S&P 500   4,117.86 (-1.11%)
DOW   33,949.01 (-0.61%)
QQQ   304.37 (-1.78%)
AAPL   151.92 (-1.77%)
MSFT   266.73 (-0.31%)
META   183.43 (-4.27%)
GOOGL   99.37 (-7.68%)
AMZN   100.05 (-2.02%)
TSLA   201.29 (+2.28%)
NVDA   222.05 (+0.14%)
NIO   10.65 (-2.47%)
BABA   105.11 (-0.37%)
AMD   84.69 (-1.42%)
T   19.16 (-0.47%)
F   13.42 (-0.22%)
MU   60.25 (-3.03%)
CGC   2.74 (-2.84%)
GE   81.96 (-0.18%)
DIS   111.78 (+0.13%)
AMC   5.72 (-7.44%)
PFE   43.98 (+0.89%)
PYPL   79.72 (-4.22%)
NFLX   366.83 (+1.07%)
S&P 500   4,117.86 (-1.11%)
DOW   33,949.01 (-0.61%)
QQQ   304.37 (-1.78%)
AAPL   151.92 (-1.77%)
MSFT   266.73 (-0.31%)
META   183.43 (-4.27%)
GOOGL   99.37 (-7.68%)
AMZN   100.05 (-2.02%)
TSLA   201.29 (+2.28%)
NVDA   222.05 (+0.14%)
NIO   10.65 (-2.47%)
BABA   105.11 (-0.37%)
AMD   84.69 (-1.42%)
T   19.16 (-0.47%)
F   13.42 (-0.22%)
MU   60.25 (-3.03%)
CGC   2.74 (-2.84%)
GE   81.96 (-0.18%)
DIS   111.78 (+0.13%)
AMC   5.72 (-7.44%)
PFE   43.98 (+0.89%)
PYPL   79.72 (-4.22%)
NFLX   366.83 (+1.07%)
S&P 500   4,117.86 (-1.11%)
DOW   33,949.01 (-0.61%)
QQQ   304.37 (-1.78%)
AAPL   151.92 (-1.77%)
MSFT   266.73 (-0.31%)
META   183.43 (-4.27%)
GOOGL   99.37 (-7.68%)
AMZN   100.05 (-2.02%)
TSLA   201.29 (+2.28%)
NVDA   222.05 (+0.14%)
NIO   10.65 (-2.47%)
BABA   105.11 (-0.37%)
AMD   84.69 (-1.42%)
T   19.16 (-0.47%)
F   13.42 (-0.22%)
MU   60.25 (-3.03%)
CGC   2.74 (-2.84%)
GE   81.96 (-0.18%)
DIS   111.78 (+0.13%)
AMC   5.72 (-7.44%)
PFE   43.98 (+0.89%)
PYPL   79.72 (-4.22%)
NFLX   366.83 (+1.07%)
S&P 500   4,117.86 (-1.11%)
DOW   33,949.01 (-0.61%)
QQQ   304.37 (-1.78%)
AAPL   151.92 (-1.77%)
MSFT   266.73 (-0.31%)
META   183.43 (-4.27%)
GOOGL   99.37 (-7.68%)
AMZN   100.05 (-2.02%)
TSLA   201.29 (+2.28%)
NVDA   222.05 (+0.14%)
NIO   10.65 (-2.47%)
BABA   105.11 (-0.37%)
AMD   84.69 (-1.42%)
T   19.16 (-0.47%)
F   13.42 (-0.22%)
MU   60.25 (-3.03%)
CGC   2.74 (-2.84%)
GE   81.96 (-0.18%)
DIS   111.78 (+0.13%)
AMC   5.72 (-7.44%)
PFE   43.98 (+0.89%)
PYPL   79.72 (-4.22%)
NFLX   366.83 (+1.07%)
NASDAQ:GERN

Geron - GERN Stock Forecast, Price & News

$3.05
-0.15 (-4.69%)
(As of 02/8/2023 12:00 AM ET)
Add
Compare
Today's Range
$3.03
$3.18
50-Day Range
$2.04
$3.40
52-Week Range
$1.00
$3.84
Volume
4.46 million shs
Average Volume
14.38 million shs
Market Capitalization
$1.16 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.50

Geron MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
80.3% Upside
$5.50 Price Target
Short Interest
Healthy
5.96% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-2.15
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.38) to ($0.36) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.07 out of 5 stars

Medical Sector

497th out of 1,026 stocks

Pharmaceutical Preparations Industry

239th out of 504 stocks

GERN stock logo

About Geron (NASDAQ:GERN) Stock

Geron Corp. operates as a biotechnology company. It develops a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies. The firm develops therapeutic products for oncology. The company was founded by Michael D. West on November 28, 1990 and is headquartered in Foster City, CA.

Receive GERN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Geron and its competitors with MarketBeat's FREE daily newsletter.

GERN Stock News Headlines

Laser breakthrough could send stock soaring 2,476%
Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%...Boeing soared 4,238%...L3Harris shot up 1,628%...
Laser breakthrough could send stock soaring 2,476%
Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%...Boeing soared 4,238%...L3Harris shot up 1,628%...
Why Is Geron (GERN) Stock Soaring 50% Today?
These 2 Nasdaq Biotechs Are Making Big Moves Wednesday
Why Is Axsome (AXSM) Up 18.6% Since Last Earnings Report?
Geron: Expect Topline MDS Data In Early January
Geron to Participate in Stifel 2022 Healthcare Conference
Geron (GERN) Q3 2022 Earnings Call Transcript
See More Headlines
Receive GERN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Geron and its competitors with MarketBeat's FREE daily newsletter.

GERN Company Calendar

Last Earnings
11/09/2021
Today
2/08/2023
Next Earnings (Estimated)
3/09/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:GERN
CUSIP
37416310
Employees
69
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$5.50
High Stock Price Forecast
$7.00
Low Stock Price Forecast
$4.00
Forecasted Upside/Downside
+80.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-116,110,000.00
Net Margins
-8,563.80%
Pretax Margin
-8,563.80%

Debt

Sales & Book Value

Annual Sales
$1.39 million
Book Value
$0.39 per share

Miscellaneous

Free Float
358,361,000
Market Cap
$1.16 billion
Optionable
Optionable
Beta
0.77

Key Executives

  • John A. Scarlett
    Chairman, President & Chief Executive Officer
  • Andrew J. Grethlein
    Chief Operating Officer & Executive Vice President
  • Olivia K. Bloom
    Chief Financial Officer, Treasurer & Executive VP
  • Faye Feller
    Chief Medical Officer & Executive Vice President
  • Stephen N. Rosenfield
    Secretary, Chief Legal Officer & Executive VP













GERN Stock - Frequently Asked Questions

Should I buy or sell Geron stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Geron in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" GERN shares.
View GERN analyst ratings
or view top-rated stocks.

What is Geron's stock price forecast for 2023?

4 Wall Street analysts have issued twelve-month price targets for Geron's stock. Their GERN share price forecasts range from $4.00 to $7.00. On average, they anticipate the company's share price to reach $5.50 in the next twelve months. This suggests a possible upside of 71.9% from the stock's current price.
View analysts price targets for GERN
or view top-rated stocks among Wall Street analysts.

How have GERN shares performed in 2023?

Geron's stock was trading at $2.42 at the beginning of the year. Since then, GERN stock has increased by 32.2% and is now trading at $3.20.
View the best growth stocks for 2023 here
.

Are investors shorting Geron?

Geron saw a drop in short interest in the month of January. As of January 15th, there was short interest totaling 22,710,000 shares, a drop of 22.2% from the December 31st total of 29,190,000 shares. Based on an average daily volume of 8,130,000 shares, the days-to-cover ratio is currently 2.8 days.
View Geron's Short Interest
.

When is Geron's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 9th 2023.
View our GERN earnings forecast
.

How were Geron's earnings last quarter?

Geron Co. (NASDAQ:GERN) announced its earnings results on Tuesday, November, 9th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.09) by $0.01. The biopharmaceutical company earned $0.11 million during the quarter, compared to analysts' expectations of $0.10 million. Geron had a negative trailing twelve-month return on equity of 110.76% and a negative net margin of 8,563.80%.

What is John A. Scarlett's approval rating as Geron's CEO?

5 employees have rated Geron Chief Executive Officer John A. Scarlett on Glassdoor.com. John A. Scarlett has an approval rating of 82% among the company's employees.

What other stocks do shareholders of Geron own?
What is Geron's stock symbol?

Geron trades on the NASDAQ under the ticker symbol "GERN."

Who are Geron's major shareholders?

Geron's stock is owned by a number of retail and institutional investors. Top institutional investors include Commonwealth Equity Services LLC (0.04%), State Board of Administration of Florida Retirement System (0.03%), WESPAC Advisors LLC (0.03%), Arizona State Retirement System (0.03%), Douglas Lane & Associates LLC (0.02%) and ProShare Advisors LLC (0.02%).
View institutional ownership trends
.

How do I buy shares of Geron?

Shares of GERN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Geron's stock price today?

One share of GERN stock can currently be purchased for approximately $3.20.

How much money does Geron make?

Geron (NASDAQ:GERN) has a market capitalization of $1.22 billion and generates $1.39 million in revenue each year. The biopharmaceutical company earns $-116,110,000.00 in net income (profit) each year or ($0.36) on an earnings per share basis.

How can I contact Geron?

Geron's mailing address is 919 EAST HILLSDALE BOULEVARD SUITE 250, FOSTER CITY CA, 94404. The official website for the company is www.geron.com. The biopharmaceutical company can be reached via phone at (650) 473-7700, via email at investor@geron.com, or via fax at 650-473-7750.

This page (NASDAQ:GERN) was last updated on 2/8/2023 by MarketBeat.com Staff